2021 Q1 Form 10-Q Financial Statement
#000156459021023501 Filed on May 05, 2021
Income Statement
| Concept | 2021 Q1 | 2020 Q1 |
|---|---|---|
| Revenue | $99.40M | $36.31M |
| YoY Change | 173.75% | 99.81% |
| Cost Of Revenue | $5.190M | -$3.500M |
| YoY Change | -248.29% | -874.34% |
| Gross Profit | $94.21M | $39.81M |
| YoY Change | 136.65% | 124.66% |
| Gross Profit Margin | 94.78% | 109.64% |
| Selling, General & Admin | $53.26M | $47.52M |
| YoY Change | 12.08% | 22.37% |
| % of Gross Profit | 56.53% | 119.36% |
| Research & Development | $147.5M | $113.0M |
| YoY Change | 30.59% | 44.63% |
| % of Gross Profit | 156.58% | 283.75% |
| Depreciation & Amortization | $3.367M | $2.850M |
| YoY Change | 18.14% | 34.5% |
| % of Gross Profit | 3.57% | 7.16% |
| Operating Expenses | $200.8M | $157.0M |
| YoY Change | 27.9% | 33.72% |
| Operating Profit | -$106.6M | -$120.7M |
| YoY Change | -11.68% | 21.62% |
| Interest Expense | -$19.98M | $10.59M |
| YoY Change | -288.67% | 242.72% |
| % of Operating Profit | ||
| Other Income/Expense, Net | -$795.0K | -$456.0K |
| YoY Change | 74.34% | 10.68% |
| Pretax Income | -$135.8M | -$118.6M |
| YoY Change | 14.46% | 22.87% |
| Income Tax | $379.0K | $409.0K |
| % Of Pretax Income | ||
| Net Earnings | -$136.1M | -$119.0M |
| YoY Change | 14.38% | 23.02% |
| Net Earnings / Revenue | -136.97% | -327.81% |
| Basic Earnings Per Share | -$2.05 | |
| Diluted Earnings Per Share | -$2.029M | -$2.05 |
| COMMON SHARES | ||
| Basic Shares Outstanding | 66.95M | 57.89M |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2021 Q1 | 2020 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $965.4M | $663.3M |
| YoY Change | 45.55% | -7.27% |
| Cash & Equivalents | $383.8M | $298.2M |
| Short-Term Investments | $581.6M | $365.1M |
| Other Short-Term Assets | $68.00M | $64.80M |
| YoY Change | 4.94% | 44.0% |
| Inventory | $12.46M | $11.38M |
| Prepaid Expenses | ||
| Receivables | $25.00M | $29.30M |
| Other Receivables | $0.00 | $125.6M |
| Total Short-Term Assets | $1.071B | $894.3M |
| YoY Change | 19.75% | 13.65% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $126.1M | $83.40M |
| YoY Change | 51.2% | 86.58% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | $129.0M | |
| YoY Change | -0.07% | |
| Long-Term Investments | $216.4M | $77.10M |
| YoY Change | 180.67% | |
| Other Assets | $8.900M | $4.900M |
| YoY Change | 81.63% | 81.48% |
| Total Long-Term Assets | $526.9M | $338.8M |
| YoY Change | 55.52% | 53.37% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $1.071B | $894.3M |
| Total Long-Term Assets | $526.9M | $338.8M |
| Total Assets | $1.598B | $1.233B |
| YoY Change | 29.58% | 22.36% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $15.70M | $14.40M |
| YoY Change | 9.03% | 13.39% |
| Accrued Expenses | $82.70M | $67.72M |
| YoY Change | 22.12% | 24.94% |
| Deferred Revenue | $25.09M | $145.3M |
| YoY Change | -82.73% | 210455.07% |
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | ||
| YoY Change | ||
| Total Short-Term Liabilities | $127.0M | $196.9M |
| YoY Change | -35.5% | 194.32% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Other Long-Term Liabilities | $382.8M | $393.8M |
| YoY Change | -2.79% | 1612.17% |
| Total Long-Term Liabilities | $382.8M | $393.8M |
| YoY Change | -2.79% | 1612.17% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $127.0M | $196.9M |
| Total Long-Term Liabilities | $382.8M | $393.8M |
| Total Liabilities | $543.2M | $624.0M |
| YoY Change | -12.95% | 415.7% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | ||
| YoY Change | ||
| Common Stock | ||
| YoY Change | ||
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $1.055B | $609.1M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $1.598B | $1.233B |
| YoY Change | 29.58% | 22.36% |
Cashflow Statement
| Concept | 2021 Q1 | 2020 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$136.1M | -$119.0M |
| YoY Change | 14.38% | 23.02% |
| Depreciation, Depletion And Amortization | $3.367M | $2.850M |
| YoY Change | 18.14% | 34.5% |
| Cash From Operating Activities | -$159.3M | -$95.15M |
| YoY Change | 67.46% | -0.65% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $16.41M | $14.10M |
| YoY Change | 16.44% | 360.8% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | -$166.0M | -$81.03M |
| YoY Change | 104.87% | -17.43% |
| Cash From Investing Activities | -$182.4M | -$95.13M |
| YoY Change | 91.77% | -6.0% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 12.65M | 55.62M |
| YoY Change | -77.26% | -84.27% |
| NET CHANGE | ||
| Cash From Operating Activities | -159.3M | -95.15M |
| Cash From Investing Activities | -182.4M | -95.13M |
| Cash From Financing Activities | 12.65M | 55.62M |
| Net Change In Cash | -329.9M | -135.3M |
| YoY Change | 143.85% | -186.47% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$159.3M | -$95.15M |
| Capital Expenditures | $16.41M | $14.10M |
| Free Cash Flow | -$175.8M | -$109.2M |
| YoY Change | 60.88% | 10.54% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2020Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2020Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2020Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2021Q1 | us-gaap |
Restricted Cash And Cash Equivalents Current Asset Statement Of Financial Position Extensible List
RestrictedCashAndCashEquivalentsCurrentAssetStatementOfFinancialPositionExtensibleList
|
us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember | |
| CY2020Q1 | us-gaap |
Restricted Cash And Cash Equivalents Current Asset Statement Of Financial Position Extensible List
RestrictedCashAndCashEquivalentsCurrentAssetStatementOfFinancialPositionExtensibleList
|
us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember | |
| CY2021Q1 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent Asset Statement Of Financial Position Extensible List
RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList
|
us-gaap:OtherNoncurrentAssetsMember | |
| CY2020Q1 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent Asset Statement Of Financial Position Extensible List
RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList
|
us-gaap:OtherNoncurrentAssetsMember | |
| CY2020Q4 | rare |
Contract Liabilities Current
ContractLiabilitiesCurrent
|
59219000 | |
| CY2020Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
2773195000 | |
| CY2020Q4 | rare |
Contract Liabilities Noncurrent
ContractLiabilitiesNoncurrent
|
7349000 | |
| CY2020Q4 | rare |
Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
|
39251000 | |
| CY2020Q4 | us-gaap |
Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
|
33306000 | |
| CY2020Q4 | rare |
Liability Related To Sale Of Future Royalties
LiabilityRelatedToSaleOfFutureRoyalties
|
335665000 | |
| CY2020Q4 | us-gaap |
Liabilities
Liabilities
|
605180000 | |
| CY2020Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
25000000 | |
| CY2020Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
67000 | |
| CY2020Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
689000 | |
| CY2020Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-1619576000 | |
| CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
1154375000 | |
| CY2020Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
1759555000 | |
| CY2021Q1 | us-gaap |
Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
|
581614000 | |
| CY2020Q4 | us-gaap |
Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
|
488007000 | |
| CY2021Q1 | rare |
Equity Investments Noncurrent
EquityInvestmentsNoncurrent
|
134756000 | |
| CY2020Q4 | rare |
Equity Investments Noncurrent
EquityInvestmentsNoncurrent
|
155375000 | |
| CY2021Q1 | us-gaap |
Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
|
81624000 | |
| CY2020Q4 | us-gaap |
Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
|
10506000 | |
| CY2021Q1 | rare |
Contract Liabilities Current
ContractLiabilitiesCurrent
|
19221000 | |
| CY2021Q1 | rare |
Operating And Finance Lease Liability Current
OperatingAndFinanceLeaseLiabilityCurrent
|
9380000 | |
| CY2020Q4 | rare |
Operating And Finance Lease Liability Current
OperatingAndFinanceLeaseLiabilityCurrent
|
8976000 | |
| CY2021Q1 | rare |
Contract Liabilities Noncurrent
ContractLiabilitiesNoncurrent
|
5868000 | |
| CY2021Q1 | rare |
Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
|
36752000 | |
| CY2020Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
112961000 | |
| CY2021Q1 | rare |
Cost Of Sales
CostOfSales
|
5188000 | |
| CY2021Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
147518000 | |
| CY2020Q1 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
47516000 | |
| CY2021Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-106569000 | |
| CY2021Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
639000 | |
| CY2020Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
2919000 | |
| CY2021Q1 | us-gaap |
Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
|
-20619000 | |
| CY2020Q1 | us-gaap |
Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
|
7668000 | |
| CY2021Q1 | rare |
Non Cash Interest Expense On Liability Related To Sale Of Future Royalties
NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties
|
8418000 | |
| CY2020Q1 | rare |
Non Cash Interest Expense On Liability Related To Sale Of Future Royalties
NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties
|
8082000 | |
| CY2021Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-795000 | |
| CY2020Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-456000 | |
| CY2021Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-135762000 | |
| CY2020Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-118616000 | |
| CY2021Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
379000 | |
| CY2020Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
409000 | |
| CY2021Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-136141000 | |
| CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-119025000 | |
| CY2021Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-2.03 | |
| CY2020Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-2.05 | |
| CY2021Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
67102342 | |
| CY2020Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
57995999 | |
| CY2021Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-136141000 | |
| CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-119025000 | |
| CY2021Q1 | us-gaap |
Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
|
-285000 | |
| CY2020Q1 | us-gaap |
Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
|
-49000 | |
| CY2021Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-348000 | |
| CY2020Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-1349000 | |
| CY2021Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
-633000 | |
| CY2020Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
-1398000 | |
| CY2020Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-120423000 | |
| CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
1154375000 | |
| CY2021Q1 | rare |
Issuance Of Common Stock Under Equity Plan Awards Net Of Tax
IssuanceOfCommonStockUnderEquityPlanAwardsNetOfTax
|
12761000 | |
| CY2020Q1 | rare |
Issuance Of Common Stock Value In Connection With License Agreement
IssuanceOfCommonStockValueInConnectionWithLicenseAgreement
|
55268000 | |
| CY2020Q1 | rare |
Issuance Of Common Stock Upon Exercise Of Warrants And Under Equity Plan Awards Net Of Tax
IssuanceOfCommonStockUponExerciseOfWarrantsAndUnderEquityPlanAwardsNetOfTax
|
380000 | |
| CY2020Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
-1398000 | |
| CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-119025000 | |
| CY2020Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
609146000 | |
| CY2021Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-136141000 | |
| CY2020Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-119025000 | |
| CY2021Q1 | rare |
Allocated Share Based Compensation Expense Net Of Capitalized Inventory Cost
AllocatedShareBasedCompensationExpenseNetOfCapitalizedInventoryCost
|
24254000 | |
| CY2020Q1 | rare |
Allocated Share Based Compensation Expense Net Of Capitalized Inventory Cost
AllocatedShareBasedCompensationExpenseNetOfCapitalizedInventoryCost
|
20155000 | |
| CY2021Q1 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-940000 | |
| CY2020Q1 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
299000 | |
| CY2021Q1 | us-gaap |
Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
|
-20619000 | |
| CY2020Q1 | us-gaap |
Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
|
7668000 | |
| CY2021Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
3367000 | |
| CY2021Q1 | rare |
Non Cash Collaboration Royalty Revenue
NonCashCollaborationRoyaltyRevenue
|
3872000 | |
| CY2020Q1 | rare |
Non Cash Collaboration Royalty Revenue
NonCashCollaborationRoyaltyRevenue
|
2615000 | |
| CY2021Q1 | rare |
Non Cash Interest Expense On Liability Related To Sale Of Future Royalties
NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties
|
8418000 | |
| CY2020Q1 | rare |
Non Cash Interest Expense On Liability Related To Sale Of Future Royalties
NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties
|
8082000 | |
| CY2021Q1 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-325000 | |
| CY2020Q1 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-463000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
|
125550000 | |
| CY2021Q1 | rare |
Increase Decrease In Accounts Payable Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherOperatingLiabilities
|
-23602000 | |
| CY2020Q1 | rare |
Increase Decrease In Accounts Payable Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherOperatingLiabilities
|
-5383000 | |
| CY2021Q1 | rare |
Increase Decrease In Contract Liabilities
IncreaseDecreaseInContractLiabilities
|
-41479000 | |
| CY2020Q1 | rare |
Increase Decrease In Contract Liabilities
IncreaseDecreaseInContractLiabilities
|
145283000 | |
| CY2021Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-159346000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-95152000 | |
| CY2021Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
16414000 | |
| CY2020Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
14096000 | |
| CY2021Q1 | us-gaap |
Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
|
405230000 | |
| CY2020Q1 | us-gaap |
Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
|
285229000 | |
| CY2021Q1 | us-gaap |
Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
|
14980000 | |
| CY2020Q1 | us-gaap |
Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
|
16600000 | |
| CY2021Q1 | us-gaap |
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
|
224240000 | |
| CY2020Q1 | us-gaap |
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
|
187600000 | |
| CY2021Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-182424000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-95125000 | |
| CY2020Q1 | rare |
Proceeds From Issuance Of Common Stock In Connection With License Agreement
ProceedsFromIssuanceOfCommonStockInConnectionWithLicenseAgreement
|
55268000 | |
| CY2021Q1 | us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
|
12761000 | |
| CY2020Q1 | us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
|
380000 | |
| CY2021Q1 | us-gaap |
Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
|
-112000 | |
| CY2020Q1 | us-gaap |
Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
|
-33000 | |
| CY2021Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
12649000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
55615000 | |
| CY2021Q1 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
-771000 | |
| CY2020Q1 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
-623000 | |
| CY2021Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-329892000 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-135285000 | |
| CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
726294000 | |
| CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
436244000 | |
| CY2021Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
396402000 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
300959000 | |
| CY2020Q1 | rare |
Operating And Finance Lease Liability From Obtaining Right Of Use Assets
OperatingAndFinanceLeaseLiabilityFromObtainingRightOfUseAssets
|
7397000 | |
| CY2021Q1 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Organization </p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ultragenyx Pharmaceutical Inc. (the Company) is a biopharmaceutical company incorporated in California on April 22, 2010. The Company subsequently reincorporated in the state of Delaware in June 2011.</p> <p style="margin-top:4pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. The Company operates as one reportable segment. The Company has three commercially approved products. Crysvita® (burosumab) is approved in the United States by the U.S. Food and Drug Administration (FDA) and in Canada for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients one year of age and older, and is approved in the European Union (EU) and the United Kingdom, for the treatment of XLH with radiographic evidence of bone disease in children one year of age and older, adolescents, and adults. In Brazil and Mexico, Crysvita is approved for treatment of XLH in adult and pediatric patients one year of age and older. Crysvita is also approved in the United States by the FDA for the treatment of fibroblast growth factor 23 (FGF23)-related hypophosphatemia in tumor-induced osteomalacia (TIO), associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in adults and pediatric patients 2 years of age and older. </p> <p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has also received FDA approval for Mepsevii<span style="font-size:12pt;">®</span> (vestronidase alfa), the first medicine approved for the treatment of children and adults with mucopolysaccharidosis VII (MPS VII), also known as Sly syndrome. In the European Union and the United Kingdom, Mepsevii is approved under exceptional circumstances for patients of all ages for the treatment of non-neurological manifestations of MPS VII. In Brazil, Mepsevii is approved for the treatment of MPS VII for patients of all ages. </p> <p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dojolvi<span style="font-size:12pt;">®</span>, formerly known as UX007, is approved in the United States and Canada for the treatment of pediatric and adult patients severely affected by long-chain fatty acid oxidation disorders (LC-FAOD). </p> <p style="margin-top:4pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the approved products, the Company has the following ongoing clinical development programs: </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.33%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:3.33%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/>DTX401 is an adeno-associated virus 8 (AAV8) gene therapy product candidate for the treatment of patients with glycogen storage disease type Ia (GSDIa);</p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.33%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:3.33%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/>DTX301 is an AAV8 gene therapy product candidate in development for the treatment of patients with ornithine transcarbamylase (OTC) deficiency, the most common urea cycle disorder;</p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.33%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:3.33%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/>UX143 (setrusumab) is a fully human monoclonal antibody that inhibits sclerostin, a protein that acts on a key bone-signaling pathway and inhibits the activity of bone-forming cells for the treatment of patients with osteogenesis imperfect (OI); </p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.33%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:3.33%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">GTX-102 is an antisense oligonucleotide (ASO), which the Company is collaborating on the development with GeneTx Biotherapeutics LLC (GeneTx) for the treatment of Angelman syndrome, a debilitating and rare neurogenetic disorder caused by loss-of-function of the maternally inherited allele of the UBE3A gene;</span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.33%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:3.33%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">UX701 is an AAV type 9 gene therapy designed to deliver stable expression of a truncated version of the ATP7B copper transporter following a single intravenous infusion to improve copper distribution and excretion from the body and reverse pathological findings of Wilson liver disease; and</span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.33%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:3.33%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">UX053 is a messenger RNA (mRNA) product candidate designed for the treatment of patients with Glycogen Storage Disease Type III (GSDIII), a disease caused by a glycogen debranching enzyme (AGL) deficiency that results in glycogen accumulation in the liver and muscle. </span></p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has sustained operating losses and expects such annual losses to continue over the next several years. The Company’s ultimate success depends on the outcome of its research and development and commercialization activities, for which it expects to incur additional losses in the future. Management recognizes that the Company will need to raise additional capital to fully implement its business plans. Through March 31, 2021, the Company has relied primarily on its sale of equity securities, its sale of future royalties, and strategic collaboration arrangements, to finance its operations.</p> <p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will likely raise additional capital through the issuance of equity, borrowings, or strategic alliances with partner companies. However, if such financing is not available at adequate levels, the Company would need to reevaluate its operating plans.</p> | |
| CY2021Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="margin-bottom:0pt;margin-top:13pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared in accordance with GAAP. The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities and the reported amounts of expenses in the consolidated financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to clinical trial accruals, fair value of assets and liabilities, income taxes, stock-based compensation, and the liability related to the sale of future royalties. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. </p> | |
| CY2021Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
383794000 | |
| CY2020Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
298190000 | |
| CY2021Q1 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
10687000 | |
| CY2020Q1 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
161000 | |
| CY2021Q1 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
1921000 | |
| CY2020Q1 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
2608000 | |
| CY2021Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
396402000 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
300959000 | |
| CY2021Q1 | us-gaap |
Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
|
1150365000 | |
| CY2020Q4 | us-gaap |
Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
|
1327662000 | |
| CY2021Q1 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
1016316000 | |
| CY2021Q1 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
68000 | |
| CY2021Q1 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
1016228000 | |
| CY2020Q4 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
1172906000 | |
| CY2021Q1 | us-gaap |
Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
|
0 | |
| CY2021Q1 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
6783000 | |
| CY2021Q1 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
5679000 | |
| CY2021Q1 | us-gaap |
Inventory Net
InventoryNet
|
12462000 | |
| CY2021Q1 | rare |
Research Clinical Study And Manufacturing Expenses
ResearchClinicalStudyAndManufacturingExpenses
|
23456000 | |
| CY2021Q1 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
33850000 | |
| CY2021Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
25393000 | |
| CY2021Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
82699000 | |
| CY2021Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
99395000 | |
| CY2021Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
99395000 | |
| CY2020Q4 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
66568000 | |
| CY2021Q1 | rare |
Contract With Customer Liability Additions During Period
ContractWithCustomerLiabilityAdditionsDuringPeriod
|
1271000 | |
| CY2021Q1 | rare |
Contract With Customer Liability Deductions During Period
ContractWithCustomerLiabilityDeductionsDuringPeriod
|
42750000 | |
| CY2021Q1 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
25089000 | |
| CY2021Q1 | rare |
Percentage Of Gross Accounts Receivable Balance
PercentageOfGrossAccountsReceivableBalance
|
0.54 | |
| CY2019Q4 | rare |
Liability Related To Sale Of Future Royalties
LiabilityRelatedToSaleOfFutureRoyalties
|
315369000 | |
| CY2020 | rare |
Non Cash Collaboration Royalty Revenue
NonCashCollaborationRoyaltyRevenue
|
12995000 | |
| CY2020 | rare |
Non Cash Interest Expense On Liability Related To Sale Of Future Royalties
NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties
|
33291000 | |
| CY2020Q4 | rare |
Liability Related To Sale Of Future Royalties
LiabilityRelatedToSaleOfFutureRoyalties
|
335665000 | |
| CY2021Q1 | rare |
Non Cash Collaboration Royalty Revenue
NonCashCollaborationRoyaltyRevenue
|
3872000 | |
| CY2021Q1 | rare |
Non Cash Interest Expense On Liability Related To Sale Of Future Royalties
NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties
|
8418000 | |
| CY2021Q1 | rare |
Liability Related To Sale Of Future Royalties
LiabilityRelatedToSaleOfFutureRoyalties
|
340211000 | |
| CY2021Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
24298000 | |
| CY2020Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
20172000 | |
| CY2021Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
8118221 | |
| CY2020Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
8585289 | |
| CY2021Q1 | us-gaap |
Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
|
144000 | |
| CY2020Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
|
429000 | |
| CY2021Q1 | us-gaap |
Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
-88000 | |
| CY2020Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
260000 | |
| CY2021Q1 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
56000 | |
| CY2020Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
689000 |
